Foot & Ankle Institute of Iowa Now Offers
Erchonia’s LunulaLaser® for the Treatment of Onychomycosis
FDA-approved, non-thermal, non-invasive, pain-free procedure with new clear nail growth in 6 months
Foot & Ankle Institute of Iowa is now accepting appointments for Erchonia’s new LunulaLaser to target Onychomycosis. The FDA-approved, non-invasive LunulaLaser targets the fungus and stimulate an average of 6.1 mm* new clear nail growth at 6 months.
Dr. Rudolph comments, “Onychomycosis is a wide spread condition that affects up to 10% of the world’s population. Erchonia’s LunulaLaser is ideal treatment because it offers effective, pain-free, non-thermal treatment—without side effects or dangerous smoke plumes as other hot lasers used to treat onychomycosis. LunulaLaser consists of (4) weekly treatments 12 minute treatments.
Erchonia’s LunulaLaser received FDA-clearance based on data obtained from 3 clinical trials. The LunulaLaser clinical trial proved 89% of patients respond to treatment.
For more information or to schedule a LunulaLaser consultation, please call (515) 223-5219.
Erchonia is the global leader in low level laser healthcare applications. For nearly two decades, Erchonia has been conducting research & development with the world’s leading physicians to advance the science of low level lasers. Erchonia created the low-level laser category after the company was granted the first low level laser FDA clearance for any indication in 2002. Prior to market introduction, all Erchonia lasers are proven to be safe and effective through independent clinical trials. Currently thousands of Erchonia’s lasers are used daily to target body fat and create a slimming effect, target onychomycosis, veterinary applications and reduce pain. For additional information, visit www.erchonia.com.